Mouse Anti-Hu/Mo VEGFR-1/Flt-1, Antagonistic
Slide this table
|Centrifuge the vial prior to opening. Reconstitute the antibody with 200 µl sterile PBS and the final concentration is 500 µg/ml.
|Stability and Storage
|Lyophilized samples are stable for 2 years from date of receipt when stored at -20°C. Reconstituted antibody can be aliquoted and stored frozen at < -20°C for at least six months without detectable loss of activity.
|This antibody was produced from a hybridoma (mouse myeloma fused with spleen cells from a mouse immunized with purified extracellular domain of recombinant human VEGFR1.
|recombinant hVEGFR1 extracellular domain
|vascular endothelial growth factor receptor-1; FLT1; FLT; VEGF receptor 1
|Endothelial cells express three different vascular endothelial growth factor (VEGF) receptors, belonging to the family of receptor tyrosine kinases (RTKs). They are named VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1), VEGFR-3 (Flt-4). Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes, dendritic cells and on trophoblast cells. The flt-1 gene was first described in 1990. The receptor contains seven immunoglobulin-like extracellular domains, a single transmembrane region and an intracellular splited tyrosine kinase domain. Compared to VEGFR-2 the Flt-1 receptor has a higher affinity for VEGF but a weaker signaling activity. VEGFR-1 thus leads not to proliferation of endothelial cells, but mediates signals for differentiation. Interestingly a naturally occuring soluble variant of VEGFR-1 (sVEGFR-1) was found in HUVEC supernatants in 1996, which is generated by alternative splicing of the flt-1 mRNA. The antibody will bind near the ligand binding site of the receptor and has antagonistic activity by blocking the binding of natural ligands.
All prices plus VAT + possible delivery charges